Jeff Lawrence, Ph.D.
30 years experience at the CEO/President/Director levels of Contract Research Organizations specializing in: Agricultural chemical, Neutraceutical, Fine chemical and Pharmaceutical research and development and product commercialization.
Mr. Wolf resides in Switzerland. During 2008 to 2012, Mr. Wolf managed Vector Assets S.A., an asset management company, which controlled companies in the mining, oil and gas, pharmaceuticals, hospitality and real estate industries.
Bcalm was originally conceived by Dr. Stephen Cox. Initial developmental work with Dr. Jeff Lawrence led to the filing of US Patent No. 6,432,172 B1, titled “Method of Treating Symptoms of Panic Attacks”
Dr. David Sinclair subsequently and independently came up with the idea for the device, and has worked with Dr. Cox on a second clinical trial.
Bcalm has been commercialized by Dr. Michael Sinclair and Geoffrey Wolf.
Dr. Stephen Cox, co-inventor of Bcalm, is a board–certified psychiatrist who has specialized in anxiety disorder for more than thirty years. He founded the non–profit medical health education organization the National Anxiety Foundation, was on the Board of Directors of the American Academy of Clinical Psychiatry, and has been on the Editorial Board of the medical journal, The Annals of Clinical Psychiatry. He began researching anxiety disorders and possible treatments in the 1980s after becoming concerned that so many people across the country time had an undiagnosed anxiety disorder and were receiving no treatment, or ineffective or wrong treatment.
Dr. Jeff Lawrence, co-inventor of Bcalm, has worked for over 30 years in the chemical and pharmaceutical industries. He has worked with Dr. Cox for over 20 years to optimize the Bcalm device and assist in its commercialization. He is currently working with the FDA to obtain approval for the use of Bcalm in the treatment of panic disorder in the United States.
Dr. David Sinclair is author of The Rest Principle: A Neurophysiological Theory of Behavior, and one of the world’s leading experts on addiction science. He independently came up with the idea of a panic device that ‘scrubs’ CO2 after expanding the scope of his research beyond alcoholism. After realizing that a patent had already been filed for such a device, he contacted Dr. Cox and they struck up a friendship, after discovering they had a lot in common. Dr Sinclair has since ran a clinical trial of an early version of Bcalm that showed clinical benefit in both full strength and weak strength devices.
Dr. Michael Sinclair qualified in medicine from the Middlesex Hospital, London in 1967 and held a number of appointments at teaching hospitals in London. He became a Registrar in Psychiatry at the Maudsley Hospital and Institute of Psychiatry of London University before entering business in 1971. He serves on the Board of Overseers (emeritus) of the Tufts University School of Medicine. He was also the chairman and founder of US based Atlantic Medical Management LLP, which managed the New York based healthcare venture fund, Atlantic Medical Capital LP. He is the Chairman of AIM traded company, Totally Plc.